Assessing tumor response to therapy
- PMID: 19380403
- DOI: 10.2967/jnumed.108.057174
Assessing tumor response to therapy
Abstract
Most anticancer drugs are effective only in subgroups of patients, and our current understanding of tumor biology does not allow us to predict accurately which patient will benefit from a specific therapeutic regimen. Various techniques have, therefore, been developed for monitoring tumor response to therapy, but measuring tumor shrinkage on CT represents the current standard. Although response assessment on CT has been refined over many years, fundamental limitations remain. Interobserver variability in tumor size measurements is still high because of difficulties in delineating tumor tissue from secondary changes in the surrounding tissues. Furthermore, CT is inaccurate in differentiating viable tumor from necrotic or fibrotic tissue. Consequently, the degree of response may be underestimated on CT. Conversely, if tumor shrinkage is short lived and followed by rapid tumor regrowth, CT may overestimate the beneficial effects of a treatment. Finally, CT is limited in characterizing responses in tumors that do not change in size during therapy. Because the growth rate of untreated human tumors varies tremendously, an unchanged tumor size after some weeks of therapy may represent a drug effect but may also indicate a slowly growing tumor that was not affected by the applied therapy. Molecular imaging with PET and the glucose analogue (18)F-FDG PET has been shown to improve response assessment in several tumor types. In malignant lymphoma, international criteria for monitoring response to therapy have recently been revised, and the (18)F-FDG signal now plays a central role in defining tumor response. In a variety of solid tumors, single-center studies have indicated that (18)F-FDG PET may provide earlier or more accurate assessment of tumor response than CT, suggesting that (18)F-FDG PET could play a significant role in personalizing the treatment of malignant tumors. However, generally accepted criteria for response assessment in solid tumors are missing, which makes it frequently impossible to compare the results of different studies. International guidelines and criteria for response assessment by (18)F-FDG PET in solid tumors are, therefore, eagerly awaited.
Similar articles
-
Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.J Nucl Med. 2009 Nov;50(11):1760-9. doi: 10.2967/jnumed.109.063321. Epub 2009 Oct 16. J Nucl Med. 2009. PMID: 19837757
-
The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.J Nucl Med. 2009 May;50 Suppl 1:64S-73S. doi: 10.2967/jnumed.108.057257. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380409 Review.
-
PET monitoring of therapy response in head and neck squamous cell carcinoma.J Nucl Med. 2009 May;50 Suppl 1:74S-88S. doi: 10.2967/jnumed.108.057208. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380408 Review.
-
PET/CT for therapy response assessment in lymphoma.J Nucl Med. 2009 May;50 Suppl 1:21S-30S. doi: 10.2967/jnumed.108.057190. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380407 Review.
-
18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.J Nucl Med. 2009 May;50 Suppl 1:89S-96S. doi: 10.2967/jnumed.108.057232. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380406 Review.
Cited by
-
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials.EJNMMI Res. 2024 Mar 27;14(1):32. doi: 10.1186/s13550-024-01093-7. EJNMMI Res. 2024. PMID: 38536511 Free PMC article.
-
A Novel Method for Evaluating Early Tumor Response Based on Daily CBCT Images for Lung SBRT.Cancers (Basel). 2023 Dec 19;16(1):20. doi: 10.3390/cancers16010020. Cancers (Basel). 2023. PMID: 38201447 Free PMC article.
-
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.Melanoma Res. 2024 Apr 1;34(2):166-174. doi: 10.1097/CMR.0000000000000952. Epub 2023 Dec 19. Melanoma Res. 2024. PMID: 38126339 Free PMC article.
-
Case report: Successful medical management of adrenocortical carcinoma with metastasis in a Maltese dog.Front Vet Sci. 2023 Jul 14;10:1142418. doi: 10.3389/fvets.2023.1142418. eCollection 2023. Front Vet Sci. 2023. PMID: 37519993 Free PMC article.
-
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.Target Oncol. 2023 Jul;18(4):543-558. doi: 10.1007/s11523-023-00979-1. Epub 2023 Jul 10. Target Oncol. 2023. PMID: 37428347 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical